News & Resources

Maximizing HCP Engagement and Access

Engaging healthcare providers (HCPs) is an important activity for pharmaceutical companies during all stages of product development. In fact, plans for maximizing HCP engagement are typically included in pharma marketing strategies. A survey targeting HCPs and other healthcare professionals reports that HCPs desire better access to different types of content through the channels and formats they use the most. This post will discuss how to strengthen your HCP engagement efforts by achieving the right balance of content, channels, and format or features.

Content—The Type HCPs Really Want
HCPs want more or better access to different types of high-quality content, including diagnostic tools, continuing education, and medical images. Pharma companies looking for ways to maximize HCP engagement should carefully consider the types of content they provide to their HCPs. Let’s discuss some of these types in detail.

Nearly 90% of HCPs access diagnostic tools at least once a month. This presents an opportunity for pharma companies who engage with HCPs to provide access to diagnostic tools through their own platforms. Reliable and accurate diagnostic applications are increasingly available through digital channels, and support HCPs in decision-making for their practice. For busy HCPs, instant access to diagnostic tools can improve their ability to not only provide care but also interact with pharma companies who implement these tools into their platforms.

More and more, continuing medical education (CME) programs have been requested by HCPs; but half of HCPs surveyed reported that they needed better access to educational content. CME appeals to HCPs who want to stay on top of developments made in their discipline, who support innovation in their practice, or who wish to learn new techniques or therapeutic approaches. The opportunity for pharma companies to provide their HCPs better access to CME content is ripe. Focus on engaging HCPs with new scientific findings and treatments that your company is involved in to form a mutually beneficial relationship.

While an abundance of medical imagery is available to HCPs—who access them at least once a month—the quality, accuracy, and validity of the medical images they access are inconsistent. Traditionally, pharma companies supply HCPs with their own branded promotional materials. However, there are many other types of medical images that HCPs find useful and that your company can provide, positioning yourself as a first-line resource.

Channels—Balancing Digital and Traditional
For pharma companies interested in maximizing HCP engagement, there is a need to adopt digital channels and become less reliant on traditional ones. Traditional channels for communicating with HCPs include meetings with sales reps, medical conferences, and pre-arranged phone calls. Many HCPs still find value in communicating through these channels; however, they fall short in meeting the HCPs’ needs to access certain content. That’s why there is a demand for pharma companies to adopt a cross-channel approach and to promote high-quality content accessible via digital channels, anytime and anywhere.

That said, there are still great opportunities for pharma companies to evolve traditional channels. Medical conferences provide important, cutting-edge information that the majority of HCPs find extremely valuable. However, attending conferences and live events often requires travel, taking HCPs away from their practice. Pharma companies can expand access to conference content by offering satellite symposia or providing access to conference reports through digital channels. And by facilitating ongoing discussions, hosting virtual panels, and providing access to conference resources and material, companies can even continue to engage HCPs after the conference.

Of course, digital or online channels are most frequently accessed by HCPs, but while most HCPs reported visiting independent websites more than once a week, they rarely accessed pharmaceutical brand websites. HCPs cited primary deterrents as a lack of interest, credibility, and trust. Herein lies an opportunity for pharma companies to beef up their current digital channels by fitting them with better quality content. A collaboration with other independent channels, specifically those established as credible, is another effective way to maximize digital engagement with HCPs.

Format and Features—Consider the User Experience
Digital content has evolved exponentially and with it, the types of formats and features used to support content. Among features that HCPs request in accessing digital content are search tools, download capabilities, visual illustrations or animations, synopses of key content, ability to filter content by disease or specialty, and the possibility to save and organize content. In other words, HCPs want customization. Pharma companies need to focus on the user experience of their online platforms, evaluate current features that support their content, and consider the list of features above. More importantly, websites and features developed to engage HCPs need to be optimized for mobile devices, providing a seamless experience. If they are not, you risk failing to capture valuable HCPs with a preference for using mobile devices.

Balancing Solutions
Ultimately, maximizing HCP engagement relies on pharma’s ability to supply HCPs with the content they crave, in the formats they like, and on the channels they prefer. A need for evolving traditional methods of communication alongside a strong digital presence is the first step. Consider collaboration with other independent channels or websites, and offer access to enduring content including diagnostic tools, CME, and visual resources. Finally, by focusing on the needs and preferences of HCPs, pharma companies not only increase quality engagement, but gain credibility, trust, and receptiveness to targeted marketing efforts.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.